Discontinuation of secondary prophylaxis in AIDS patients with disseminated non-tuberculous mycobacteria infection

Journal of Microbiology, Immunology and Infection

Volumn 37, Issue 1, 2004, Pages 50-56

  Liao, Chung Hsin ^a   Chen, Mao Yuan ^a   Hsieh, Szu Min ^a   Sheng, Wang Hwei ^a   Hung, Chien Ching ^a,b   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

AIDS; Highly active antiretroviral therapy; Mycobacterium avium complex; Mycobacterium kansasii; Non tuberculous mycobacteria; Prophylaxis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; ASCITES; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD; BONE MARROW; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PERICARDIAL EFFUSION; PLASMA; PROPHYLAXIS; TAIWAN; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL;

EID: 1842783151     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chin DP, Reingold AL, Stone EN, Vittinghoff E, Horsburgh CR, Simon EM, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994;170:578-84.
2. Rossi M, Flepp M, Schiffer V, Egloff N, Bucher H, Vernazza P, et al; Swiss HIV Cohort Study. Disseminated Mycobacterium avium complex infection in the Swiss HIV cohort study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med Wkly 2001;131:471-7.
3. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-5.
4. Horsburgh CR Jr, Gettings J, Alexander LN, Lennox JL. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001;33:1938-43.
5. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep 2002;51(RR-8):1-52.
6. Tumbarello M, Tacconelli E, de Donati KG, Bertagnolio S, Longo B, Ardito F, et al. Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies. Eur J Clin Microbiol Infect Dis 2001;20:498-501.
7. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
8. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gertoft J, Pradier C, et al; European HIV Cohorts. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137: 239-50.
9. Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002;34:662-7.
10. Shafran SD, Mashinter LD, Phillips P, Lalonde RG, Gill MJ, Walmsley SL, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002;137: 734-7.
11. Hsieh SM, Hung CC, Chen MY, Hsueh PR, Chang SC, Luh KT. Clinical features and outcome in disseminated mycobacterial diseases in AIDS patients in Taiwan. AIDS 1998; 12:1301-7.
12. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
13. Goldschmidt RH, Hearst N, Chambers DB. Rifabutin prophylaxis against Mycobacterium avium complex infection. N Engl J Med 1994;330:436-8.
14. Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE 3rd. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;165:577-80.
15. Pettipher CA, Karstadedt AS, Hopley M. Prevalence and clinical manifestations of disseminated Mycobacterium avium complex infection in South Africans with acquired immunodeficiency syndrome. Clin Infect Dis 2001;33:2068-71.
16. Hung CC, Chen MY, Hsieh SM, Sheng WH, Chang SC. Clinical spectrum, morbidity and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J Acquir Immune Defic Syndr 2000;24:378-85.
17. Lopez Bemaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC, Martinez E, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med 2001;344:159-67.
18. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001;344:168-74.
19. Sackoff J, McFarland J, Su S, Bryan E. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. J Acquir Immune Defic Syndr 1998;19:387-92.
20. Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex with antiretroviral therapy-induced increases in CD4+ cell count. Ann Intern Med 2000; 133:493-503.
21. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000;342:1085-92.
22. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000;14:383-6.
23. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998;178: 1446-9.
24. Hadad DJ, Lewi DM, Pignatari ACC, Martins MC, Vitti W, Arbeit RD. Resolution of Mycobacterium avium complex bacteremia following highly active antiretroviral therapy. Clin Infect Dis 1998;26:758-9.
25. Cinti SK, Kaul DR, Sax PE, Crane LR, Kazanjian PH. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis 2000;30:511-4.
26. Murray R, Mallal S, Heath MC, French M. Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001;20:199-201.